Interventional treatment of gastrointestinal neuroendocrine tumours

Håkan Ahlman, B. Wängberg, S. Jansson, S. Friman, M. Olausson, Ulf Tylen, O. Nilsson

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Neuroendocrine (NE) tumours of the gastrointestinal tract (carcinoids and endocrine pancreatic tumours) are rare diseases. In the presence of liver metastases these patients may suffer from disabling symptoms due to hormone overproduction. Patients with localized disease can be resected for cure and also patients with liver metastases can undergo potentially curative tumour resection. However, long-term follow-up of the latter cases indicates frequent recurrence of tumour. Using close biochemical monitoring of tumour markers combined with newer techniques for tumour visualization, these recurrences can often be diagnosed at an early stage so that repeat surgical procedures can be performed. During the last years very active surgery has been recommended for NE tumours, many of which have a relatively slow growth. Even in patients not amenable to curative liver surgery, debulking can be considered if the main tumour burden can be safely excised. The primary aim of this type of treatment is palliation of hormonal symptoms. An important question is whether the aggressive treatment actually prolongs survival. No prospective studies have been performed. Such studies are hampered by the lack of strict surgical programs running over long periods and the relative rarity of NE tumours. Liver transplantation may be another treatment modality in selected cases. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish (US)
Pages (from-to)59-68
Number of pages10
Issue numberSUPPL. 1
StatePublished - Jul 2000
Externally publishedYes


  • Carcinoid
  • Endocrine pancreatic tumour
  • Hepatic arterial embolization
  • Liver transplantation
  • Surgical treatment

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Interventional treatment of gastrointestinal neuroendocrine tumours'. Together they form a unique fingerprint.

Cite this